Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world …
M Palumbo, A Giammanco, F Purrello… - Frontiers in Molecular …, 2022 - frontiersin.org
Proprotein convertase subtilisin/kexin type 9 (PCSK9), beyond regulating LDL cholesterol
(LDL-c) plasma levels, exerts several pleiotropic effects by modulating lipid metabolism in …
(LDL-c) plasma levels, exerts several pleiotropic effects by modulating lipid metabolism in …
Integrated omics approach for the identification of HDL structure-function relationships in PCSK9-related familial hypercholesterolemia
M Darabi, M Lhomme, M Ponnaiah… - Journal of clinical …, 2023 - Elsevier
Background The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in
dyslipidemia may go beyond its immediate effects on low-density lipoprotein receptor (LDL …
dyslipidemia may go beyond its immediate effects on low-density lipoprotein receptor (LDL …
Lipid lowering therapy and circulating PCSK9 concentration
T Nozue - Journal of atherosclerosis and thrombosis, 2017 - jstage.jst.go.jp
Hypercholesterolemia, particularly an increase in low-density lipoprotein cholesterol (LDL-
C) levels, contributes substantially to the development of coronary artery disease and the …
C) levels, contributes substantially to the development of coronary artery disease and the …
Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence
Proprotein convertase subtilisin kexin type 9 (PCSK9) belongs to the proprotein convertase
family. Several studies have demonstrated its involvement in the regulation of low-density …
family. Several studies have demonstrated its involvement in the regulation of low-density …
Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
RJ Konrad, JS Troutt, G Cao - Lipids in health and disease, 2011 - Springer
Background During the past decade, proprotein convertase subtilisin kexin type 9 (PCSK9)
has been identified as a key regulator of serum LDL-cholesterol (LDL-C) levels. PCSK9 is …
has been identified as a key regulator of serum LDL-cholesterol (LDL-C) levels. PCSK9 is …
Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells
F Lalanne, G Lambert, MJA Amar, M Chétiveaux… - Journal of lipid …, 2005 - ASBMB
Mutations in Proprotein Convertase Subtilisin Kexin 9 (PCSK9) have been associated with
autosomal dominant hypercholesterolemia. In vivo kinetic studies indicate that LDL …
autosomal dominant hypercholesterolemia. In vivo kinetic studies indicate that LDL …
Treatment with PCSK9 inhibitors in patients with familial hypercholesterolemia lowers plasma levels of platelet-activating factor and its precursors: a combined …
A Di Minno, RC Orsini, M Chiesa, V Cavalca… - Biomedicines, 2021 - mdpi.com
Introduction: Familial hypercholesterolemia (FH) is characterized by extremely high levels of
circulating low-density lipoprotein cholesterol (LDL-C) and is caused by mutations of genes …
circulating low-density lipoprotein cholesterol (LDL-C) and is caused by mutations of genes …
Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
R Schulz, KD Schlüter, U Laufs - Basic research in cardiology, 2015 - Springer
The proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising
treatment target to lower serum cholesterol, a major risk factor of cardiovascular diseases …
treatment target to lower serum cholesterol, a major risk factor of cardiovascular diseases …
PCSK9 and its modulation
CJ Cui, S Li, JJ Li - Clinica chimica acta, 2015 - Elsevier
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a newly-recognized protein, plays a
key role in regulating cholesterol homeostasis. PCSK9 reduces hepatic low-density …
key role in regulating cholesterol homeostasis. PCSK9 reduces hepatic low-density …
Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: a single center real-world study
G Iannuzzo, A Buonaiuto, I Calcaterra, M Gentile… - Nutrition, Metabolism …, 2022 - Elsevier
Background and aims Familial hypercholesterolemia (FH) is an autosomal dominant
disease that leads to cardiovascular (CV) disease. Proprotein convertase subtilisin/kexin …
disease that leads to cardiovascular (CV) disease. Proprotein convertase subtilisin/kexin …
相关搜索
- pcsk9 inhibitors familial hypercholesterolemia
- pcsk9 inhibitors plasma levels
- plasma levels familial hypercholesterolemia
- pcsk9 inhibitors combined metabolomic
- combined metabolomic familial hypercholesterolemia
- causative mutations familial hypercholesterolemia
- plasma levels lipoprotein cholesterol
- plasma levels combined metabolomic
- plasma levels low density
- pcsk9 inhibition lipoprotein cholesterol
- clinical evidence lipoprotein metabolism
- ldl clearance cultured cells
- lipoprotein production cultured cells
- pcsk9 inhibitors hypercholesterolemia subjects